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Carotid Endarterectomy Versus
Carotid Artery Stenting
Case Closed.Now What!?*
Robert D. Saﬁan, MD
Royal Oak, Michigan
The answer to the question “What is the optimal manage-
ment of patients with carotid artery disease?” remains hotly
debated and contentious. In the 1990s, the elements of
this debate were focused on the relative merits of carotid
endarterectomy (CEA) versus medical therapy (basically,
aspirin), which most physicians considered settled by 4
randomized clinical trials in patients with symptomatic
(1,2) and asymptomatic (3,4) carotid stenosis. Taken to-
gether, these trials formed the base of evidence that sup-
ported the recommendations for CEA in symptomaticSee page 163carotid stenosis >50% and in asymptomatic carotid stenosis
>70%. In the last 15 years, the ﬁndings of these studies have
been challenged on the basis of 2 important therapeutic
innovations: one in pharmacological approaches to coronary,
peripheral, and cerebrovascular atherosclerosis, and the other
in the development of minimally invasive techniques for
carotid revascularization relying on carotid artery stenting
(CAS) and embolic protection devices (EPDs). From a
clinical trials perspective alone, more than $100 million have
been devoted to studies of the technique of carotid revascu-
larization, whereas there are no large-scale clinical trials of
optimal medical therapy for stroke prevention in patients
with severe carotid stenosis.
In this issue of JACC Cardiovascular Interventions, Brooks
et al. (5) report the culmination of 10 years of follow-up in
189 patients randomized to CEA versus CAS in the
“Kentucky trial”; in-hospital outcomes and vessel patency at
2 years were previously reported in symptomatic (6) and
asymptomatic (7) patients. The principle ﬁndings of this
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or CAS, and the risk of late myocardial infarction (MI)
was highest among patients who presented initially with
symptomatic carotid stenosis (hazard ratio: 2.32, 95% con-
ﬁdence interval: 1.30 to 4.15; p ¼ 0.005) and who were
assigned to CEA (hazard ratio: 2.27, 95% conﬁdence in-
terval: 1.35 to 3.81; p ¼ 0.002). The authors conclude that
CEA and CAS provide equal protection for prevention of
ipsilateral stroke, and that CAS may be superior to CEA for
preserving long-term event-free survival. The strengths of
the study are the long duration of follow-up (10 years), the
randomized allocation of treatment, independent neuro-
logical evaluation, and the interdisciplinary collaboration
between neurosurgeons, cardiologists, and neurologists.
The weaknesses of the study are the small number of ran-
domized patients (n ¼ 189) and patients eligible for follow-
up (n ¼ 173), single-center enrollment, performance of
CAS without EPDs, lack of information about the risk
proﬁle of the patients, and the exceedingly high late mor-
tality (50.2%).
Although proponents of CAS may cheer this study, I ﬁnd
it somewhat enigmatic in some respects and compelling in
others. First, the original cohort of 189 patients consisted of
104 symptomatic patients (55%) and 85 asymptomatic
patients (45%); the risk of periprocedural stroke was zero
(6,7). These are remarkably excellent results, particularly in
symptomatic patients. For comparative purposes, the risk of
periprocedural stroke was 4.4% in high-risk CAS patients
(with EPDs) in the BEACH (Boston Scientiﬁc Embolic
Protection Carotid Stenting Trial for High-Risk Surgical
Patients) (8) (using the same stent that was used in the
Kentucky trial), 6.2% (after CAS) and 7.9% (after CEA) in
the randomized SAPPHIRE (Stenting and Angioplasty
With Protection in Patients at High Risk for Endarterec-
tomy) trial (9); and 4.1% (after CAS) and 2.3% (after CEA)
in the CREST (Carotid Revascularization Endarterectomy
Versus Stenting Trial) in standard-risk patients (10).
Although it is possible that EPDs contributed to the risk of
periprocedural stroke after CAS, this position would be
difﬁcult to defend in the context of the declining risk of
stroke with contemporary proximal and distal EPDs, and
also deﬁes the current national coverage determination
policy mandating the use of EPDs in the United States.
Second, the 10-year mortality of 50.2% contrasts sharply
with the 5% risk of death/stroke at 4 years in the CREST
trial (10), and with the 20% to 24.2% risk of death at 3 years
in the SAPPHIRE trial (9), and suggests that carotid revas-
cularization trials might need to be extended to 5 to 10 years
of follow-up. Finally, Figure 2 of Brooks et al. (5) is very
compelling; it also supports the need for follow-up beyond 4
years, at which time both survival curves begin to diverge.
More importantly, Figure 2 appears to link symptomatic
carotid stenosis with subsequent acute MI, suggesting that
unstable plaque in the carotid arteries may be a marker for
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170vulnerable plaque in the coronary arteries, and that the period
of vulnerability may last for several years.
On considering the Kentucky trial and the universe of CAS
trials, I believe that CAS and CEA have reached clinical
equipose as strategies for carotid revascularization.case
closed! Our mission now should turn to study of medical
therapies for carotid artery disease, and to noninvasive and
invasive imaging tools to allow us to characterize plaque in
the carotid circulation (and elsewhere). We know that many
patients have unstable carotid plaque and may be at risk for
stroke, even in the absence of severe stenosis or symptoms
(11,12). Important studies in the coronary (13) and renal
(14) circulation have helped deﬁne optimal medical therapy
for preventing major cardiovascular events, so it is appro-
priate to consider such therapies in future clinical trials to
deﬁne the role of optimal medical therapy and revasculari-
zation for patients with carotid artery disease; hopefully, the
CREST-2 trial will acquire funding to do so. Although
revascularization will play an important role in alleviating
stenosis and passivating plaque in the carotid arteries, sys-
temic therapies will clearly be important, particularly for
stabilizing plaque locally and in remote vascular beds.
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